Research Article

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Che-Pin Chang,1 Yuan-Chih Su,2 Mei-Chen Lin,2 and Sheng-Teng Huang1,3,4,5,6,7

1Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan
2Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
3School of Chinese Medicine, China Medical University, Taichung, Taiwan
4An-Nan Hospital, China Medical University, Tainan, Taiwan
5Chinese Medicine Research Center, China Medical University, Taichung, Taiwan
6Research Center for Chinese Herbal Medicine, China Medical University, Taichung, Taiwan
7Cancer Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan

Correspondence should be addressed to Sheng-Teng Huang; sheng.teng@yahoo.com

Received 22 June 2019; Revised 15 September 2019; Accepted 17 October 2019; Published 21 November 2019

Copyright © 2019 Che-Pin Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic kidney disease (CKD) is a serious complication affecting patients with chronic hepatitis. The effectiveness of CHM for the prevention of CKD in hepatitis patients remains unclear. Therefore, we conducted a retrospective cohort study to investigate the effectiveness of CHM in preventing the development of CKD in hepatitis patients. From a subdataset of the Taiwan National Health Insurance Research Database (NHIRD), we included 19,409 patients newly diagnosed with hepatitis B and hepatitis C between the years 2000 and 2010. After exclusion criteria and 1:1 propensity score matching process, we compared demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts. Statistical analysis was applied to evaluate the differences in characteristic distributions and to compare the cumulative incidence of CKD between the CHM and non-CHM cohorts. This study showed that the patients suffering from hepatitis C with CHM treatment more than 90 days as an adjuvant therapy combined with western medical treatment modalities exhibited a decreased risk of developing CKD (hazard ratio (HR) = 0.40, 95% confidence interval (CI) = 0.21–0.76, p value <0.01). The Kaplan–Meier curve revealed a lower cumulative incidence rate of CKD (p value = 0.004) for the CHM cohort. For further reference, we herein offer the ten most frequently prescribed single herbs and herbal formulas; as such, Salviae miltiorrhizae and Jia-Wei-Xiao-Yao-San were the most commonly prescribed single herb and formula, respectively. This nationwide retrospective cohort study provides evidence that CHM is an effective adjuvant treatment to decrease the risk of developing CKD in hepatitis C patients.

1. Introduction

Hepatitis is a serious issue facing the global health care community, with the hepatitis B virus (HBV) and hepatitis C virus (HCV), in particular, accounting for 96% of all hepatitis mortalities. As reported by World Health Organization (WHO) in 2015, an estimated 257 million people suffered from chronic hepatitis B (CHB) worldwide, while 71 million people suffered from chronic hepatitis C (CHC) [1].

According to two previous nationwide cohort studies investigating CHB and CHC patients in Taiwan, the risk of developing chronic kidney disease (CKD) was approximately 2.3-folds higher in the CHB cohort compared with the non-CHB cohort, while that risk was 1.66-fold higher in the CHC cohort than the non-CHC cohort [2, 3], indicating that chronic hepatitis patients have an elevated risk of developing CKD. Moreover, hepatitis patients associated with CKD will present enhanced obstacles to treatment, and an
increased mortality rate, both of which further increase the economic burden placed on health care systems.

HBV infection not only affects liver function but also induces HBV-associated glomerulonephritis with several renal manifestations, particularly membranous nephropathy (MN). The HBV may interact with pre-existing host factors leading to a possible increase in morbidity and mortality [4]. HCV infection increases the risks of developing CKD and progression to end-stage renal failure (ESRF), associated with an elevated mortality rate observed in kidney dialysis and transplant recipients. Meanwhile, Solid et al. found that CHC patients with CKD G1-G5 and end-stage renal disease (ESRD) demonstrate a three-fold increased mortality rate than non-CKD patients. In a separate study of dialysis patients, the HCV cohort exhibited a higher adjusted hazard ratio (aHR) for mortality than the non-HCV cohort [5, 6].

Medical options for the treatment of CHB generally range from the injected form of interferon-α to the oral forms of nucleoside analogs (NAs). NAs used in the treatment of CHB patients are generally considered effective and convenient due to their oral administration and aside from telbivudine, exhibit minimal negative effects on renal function [7, 8]. However, with progression to CKD, interferon-α is not suitable due to poor tolerance, injection risks, and low effectiveness. Some NAs must be adjusted according to renal function (creatinine clearance <50 mL/min), and nephrotoxicity with adefovir and tenofovir treatments must be considered [8, 9].

For the decade prior to the development of direct-acting antivirals (DAAs), interferons (IFN), or Peginterferons (PEG-IFN) combined with ribavirin were the primary therapeutic modalities for HCV. Early DAAs, prevalent from 2011 to 2013, still required combination with PEG-IFN [10]. Both IFN and ribavirin are metabolized through the kidneys, thus increasing the complexity of treating HCV patients with CKD, and demonstrate poor effectiveness when associated with ESRF and hemodialysis [11].

Due to enhanced treatment complexity, the management of hepatitis patients with CKD will inevitably result in higher medical expenses incurred by health care systems. A U.S. study reported that the health care utilization rate was higher for CHB-CKD patients, with financial expenditures 3 to 5 times higher compared to non-CKD patients [12]. Furthermore, a retrospective cohort study of 35,965 HCV patients concluded that HCV patients with CKD had higher health care utilization rates and medical costs [5]. A separate retrospective cohort study of 3,438 HCV patients receiving oral DAAs revealed that those with CKD also incurred higher health care costs compared with non-CKD HCV patients [13].

The development of new NAs and DAAs has significantly increased the response rate for both HBV and HCV patients with CKD; however, there are limitations primarily related to their high expenses. As such, patients in Taiwan often seek complementary therapy from TCM, which is widely covered by the National Health Insurance system. Previous studies have revealed that nearly 37% of patients with HBV and 66% of patients with HCV utilized Chinese herbal medicine (CHM) as an adjuvant therapy in Taiwan [14, 15]. In addition, a recent study has suggested that CHM could be considered an effective adjunct to prolong the lifespan of patients with CKD [16]. However, despite the increased popularity of CHM as complimentary therapy, it remains unclear whether CHM can prevent the development of CKD in patients suffering from CHB and CHC.

Thus, the aim of the present study is to investigate CKD incidence among CHB and CHC patients between a CHM and non-CHM cohort by analyzing one million cases recorded in the Longitudinal Health Insurance Database (LHID2010) of the Taiwan NHI. Furthermore, we have collected and analyzed the associated CHM prescription patterns to provide prescription guidance for clinical practitioners and direction for future research.

2. Materials and Methods

2.1. Data Source. The Taiwan National Health Insurance (NHI), covering more than 99% of the population, set up the National Health Insurance Research Database (NHIRD) in 1995. The database contains outpatient treatment records, various hospitalization data, prescribed medications, and other medical data for each case; importantly, the database records of outpatient visits also include TCM outpatient service.

For this study, data from the Longitudinal Health Insurance Database (LHID) were used, which randomly selects one million subjects from the NHIRD, containing cases with age and gender distributions similar to the original database. To ensure the privacy of individuals, identification numbers are encrypted before the database is released. The diagnoses are coded according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). The Research Ethics Committee of China Medical University and Hospital in Taiwan approved this study (CMUH-104-REC2-115-R3).

2.2. Study Population. The population included in this study were patients newly diagnosed with hepatitis (HBV, ICD-9-CM: 070.22, 070.23, 070.32, 070.33, and V02.61; HCV, ICD-9-CM: 070.41, 070.44, 070.51, 070.54, and V02.62) during the period of 2000 to 2010. The CHM users were defined as patients with at least 30 days prescription of CHM, and the first date of CHM prescription was set as index date during 2000 to 2012. We then categorized the hepatitis patients into two cohorts, with or without use of CHM after hepatitis diagnosis. All subjects selected were over 18 years of age and followed up to CKD occurrence. The expired date was set as the patients was dead, withdrawn by NHIRD or out of Dec 31, 2013.

2.3. Primary Outcome. The primary outcome of this study was patients newly diagnosed with CKD (ICD-9-CM: 250.4, 274.1, 283.11, 403.1, 404.2, 404.3, 440.1, 442.1, 447.3, 572.4, 580–588, 642.1, and 646.2) after hepatitis diagnosis. As the risk of outcome may be influenced by comorbidities and the usage of the medicine, histories of hypertension (ICD-9-CM: 401–405), diabetes mellitus (ICD-9-CM: 250), coronary artery disease (ICD-9-CM: 410–414), hyperlipidemia (ICD-
2. CHM prescription days less than 30 days (the index date (n = 4133))

2.4. Matching. For each newly diagnosed chronic hepatitis patient with CHM treatment, we used propensity score matching at 1:1 to select the corresponding matched non-CHM users. Propensity score calculated the probability by using the logistic regression model and the variables including age, gender, urbanization, comorbidities, and medications mentioned above.

2.5. Statistical Analyses. To compare the differences in demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts, chi-squared test and t-test were used for category and continuous variables, respectively. We then calculated the risk of CKD between CHM and non-CHM cohorts. The crude and adjusted Cox proportional hazard models were demonstrated by hazard ratios (HRs) and aHRs with 95% confidence intervals (CIs). The Kaplan–Meier method was applied to measure cumulative incidence curves, and the log-rank test was used to evaluate the difference between the two curves and plotted by R studio (3.5.2). The network plot analysis by the open source free software, NodeXL (http://nodexl.codeplex.com/), revealed the associations of any two herbs and CHM formulas. The statistical analysis ran with type I error α = 0.05 using the statistical software package, SAS, version 9.4 (SAS Institute, Inc., Cary, NC).

3. Results

3.1. Demographic Characteristics. Of the one million individual cases recorded in the LHID, 19,409 adults diagnosed with hepatitis between 2000 and 2010 were identified. After exclusion criteria and determination of CHM use, those patients were classified into two groups, CHM and non-CHM users. With propensity score matching by sex, age, urbanization, comorbidities, and medications, the CHM and non-CHM cohorts each consisted of 2,710 subjects (Figure 1). The study population of CHM users and non-CHM users, shown in Table 1, were approximately 60% male with a mean age of 53.2 years. In terms of medication use, more than 50% of hepatitis patients were treated for CKD, followed by diabetes mellitus (DM). The only covariate which showed a significant difference between the two groups was age (p value = 0.01).

3.2. The Risk Factors and Cumulative Incidence of CKD in Patients with Hepatitis. As shown in Table 2, patients diagnosed with CKD after hepatitis diagnosis were filtered out, and Cox model was used to adjust the HR of CKD incidence. The results of the study revealed that 318 hepatitis patients in the non-CHM cohort, and 452 patients in the CHM cohort developed CKD. After adjustment for gender, age, urbanization, comorbidities, and medications, patients in the CHM cohort exhibited a lower cumulative incidence of CKD (aHR = 0.69, p value ≤ 0.001, 95% CI = 0.59–0.8) in comparison with the non-CHM cohort. Of note, males had a higher risk of developing CKD, while age was also found to be highly correlated to increased incidence of CKD.

With regards to comorbidities, patients with heart failure (aHR = 1.61, 95% CI = 1.23–2.11), diabetes mellitus (aHR = 1.55, 95% CI = 1.31–1.84), liver cirrhosis (aHR = 1.54, 95% CI = 1.29–1.83), and hypertension (aHR = 1.36, 95% CI = 1.14–1.62) demonstrated significant differences (p value < 0.001) in the development of CKD. It is worth noting that only DM medication increased the risk of developing CKD among hepatitis patients (aHR = 1.41, 95% CI = 1.18–1.68, p value < 0.001). HBV drugs had no significant effect to prevent development of CKD (p value = 0.15); however, HCV, statin, and CKD medications reduced the risk of developing CKD in patients with hepatitis.

Multivariable stratified analyses were applied to verify the association of hepatitis patients with CHM treatment to reduce CKD risk for those comorbidities. The results demonstrated statistical significance for hepatitis patients
and heart failure (aHR < 0.5) benefitted more from CHM, we further analyzed the HR of the non-CHM cohort. (Figure 2), indicating that the CHM cohort indeed had a lower risk of developing CKD compared with the non-CHM cohort in patients with hepatitis associated with or without comorbidities including hypertension (aHR = 0.69, 95% CI = 0.54–0.88; aHR = 0.70, 95% CI = 0.58–0.85), diabetes (aHR = 0.73, 95% CI = 0.60–0.90; aHR = 0.67, 95% CI = 0.54–0.84), liver cirrhosis (aHR = 0.79, 95% CI = 0.67–0.94; aHR = 0.50, 95% CI = 0.36–0.68), and heart failure (aHR = 0.73, 95% CI = 0.62–0.85; aHR = 0.51, 95% CI = 0.31–0.86) between these two cohorts. These results indicate that CHM significantly decreases the CKD risk in hepatitis patients associated with or without comorbidities including hypertension, diabetes mellitus, liver cirrhosis, and heart failure (Supplementary Table 1).

Additionally, the cumulative incidence of CKD, as calculated by the Kaplan–Meier method, revealed a significant difference (p value < 0.05) between the CHM cohort and the non-CHM cohort in patients with hepatitis (Figure 2), indicating that the CHM cohort indeed had a lower cumulative incidence of CKD compared with the non-CHM cohort.

In order to clarify whether a specific type of hepatitis benefitted more from CHM, we further analyzed the HR of HBV, HCV, and HBV/HCV coinfection patients, as shown in Table 3. Notably, we found that CHM had reduced the risk of CKD incidence in the HCV (p < 0.001) and HBV/HCV coinfection (p < 0.05) subgroups; meanwhile, the aHR of the HBV subgroup was 0.81, demonstrating no statistical significance (p > 0.05). Furthermore, CHM users among hepatitis patients had longer follow-up periods represented by higher person years (15533 PY) compared with those in non-CHM cohort (9069 PY). This finding indicates that CHM may provide more protective effects to the renal function of CHC patients in particular, thereby reducing the risk of developing CKD. Considering the combination treatment of CHM and western medicine in HBV, HCV, and HBV/HCV coinfection patients (Table 4), HCV patients with western medicine (HCV drugs) treatment only (aHR = 0.66, 95% CI = 0.53–0.81), and patients receiving both CHM and HCV western medicine treatment (aHR = 0.40, 95% CI = 0.21–0.76) had significantly decreased risk of developing CKD. This indicates that CHM may indeed alleviate the risk of CKD in HCV patients.

In this study, the CHM users were defined as with at least 30 days prescription of CHM after hepatitis diagnoses. In Table 5, we stratified the prescription days of CHM users into 30 to 60 days, 60 to 90 days, and more than 90 days. We discovered that CHM users with at least 90 days of CHM consumption had significant lower risk of developing CKD compared with non-CHM users (aHR = 0.58, 95% CI = 0.49–0.69). Besides, there was a trend effect with lower CKD risk in parallel with CHM consumption periods (p for trend < 0.001).

### 3.3. Top Ten Single Herbs and Formulas

The top ten single herbs and formulas prescribed by TCM practitioners for the treatment of hepatitis are listed in Table 6. The three most frequently prescribed single herbs were *Salvia miltiorrhiza*, *Corydalis yanhusuo*, and *Radix et Rhizoma Rhei*. The average days of prescription for single herbs ranged from 7.1 to 9.2 days. The three most frequently prescribed formulas were Jia-Wei-Xiao-Yao-San (JWXYS), Xiao-Chai-Hu Tang (XCHT), and Shu-Jing-Huo-Xue-Tan (SJHXT). The average days of prescription for formulas ranged from 7 to 9 days, very similar to single herbs. To clarify the association between CHM and CKD, the top ten single herbs and formulas for each hazard ratio of developing CKD are presented in Table 7. Except *Astragalus Radix*, *Ban-Xia-Xie-Xin-Tang*, and *Long-Dan-Xie-Gan-Tang*, the single herbs and formulas led to significant lower risk of developing CKD (all of p < 0.05). A network analysis of the thirty most frequently prescribed single herbs and formula combinations is shown in Figure 3, revealing JWXYS and SM, as well as *Olibanum* and *Myrrha* as the most frequent combinations.

### 4. Discussion

This is the first large-scale nationwide cohort study exploring the association between CHM therapy and incidence of CKD in hepatitis patients. The results of the study reveal that CHM, as an adjuvant therapy for patients with hepatitis,
indeed offered protective effects and prevented the development of CKD, particularly in the HCV subtype.

There are several mechanisms at play in hepatitis patients. In particular, HBeAg is prone to combine with host antibodies, forming an immune-complex which affects renal function and induces the inflammatory process resulting in secondary MN, the most common renal manifestation in patients with HBV [17]. Approximately 40% to 50% of MN in adults results in nephrotic syndrome, eventually progressing to ESRD within a period of 6 to 13 years [18]. Thus, HBeAg seroconversion may be critical in the prevention of renal damage. As reported by Chen et al., HBV patients without NAs treatment will more easily develop ESRD [19]. Meanwhile, HCV can induce renal dysfunction via direct infection of kidney tissue, lymphotropism, and cryoglobulinemia [10]. HCV directly infects kidney tissue via CD81 expression on its surface to induce cell apoptosis [20]. Type II mixed cryoglobulinemia, originating from IgG-IgM complexes, is the primary manifestation in HCV patients, predominantly inducing type I membranoproliferative glomerulonephritis (MPGN) as a result of cryoglobulinemic vasculitis [10, 21].

Table 2: Risk factors of CKD among hepatitis patients.

| Variable          | CKD Event no. | Crude HR 95% CI | p value | Adjusted§ HR 95% CI | p value |
|-------------------|---------------|-----------------|---------|---------------------|---------|
| CHM               |               |                 |         |                     |         |
| No                | 318           | 1 (Reference)   |         | 1 (Reference)       |         |
| Yes               | 452           | 0.8 (0.69–0.93) | 0.004   | 0.69 (0.59–0.8)     | <0.001  |
| Gender            |               |                 |         |                     |         |
| Female            | 312           | 1 (Reference)   |         | 1 (Reference)       |         |
| Male              | 458           | 0.9 (0.78–1.04) | 0.14    | 1.26 (1.08–1.48)    | 0.003   |
| Age, year         |               |                 |         |                     |         |
| 18–44             | 108           | 1 (Reference)   |         | 1 (Reference)       |         |
| 45–59             | 240           | 2.31 (1.84–2.9) | <0.001  | 2.12 (1.67–2.69)    | <0.001  |
| ≥60               | 422           | 4.81 (3.89–5.94) | <0.001  | 3.59 (2.78–4.64)    | <0.001  |
| Urbanization      |               |                 |         |                     |         |
| 1 (highest)       | 164           | 1 (Reference)   |         | 1 (Reference)       |         |
| 2                 | 227           | 1.1 (0.9–1.35)  | 0.35    | 1.12 (0.91–1.37)    | 0.29    |
| 3                 | 109           | 1.02 (0.8–1.3)  | 0.89    | 0.98 (0.77–1.25)    | 0.85    |
| 4 (lowest)        | 270           | 1.39 (1.14–1.68) | <0.001  | 1.14 (0.93–1.38)    | 0.21    |
| Comorbidity       |               |                 |         |                     |         |
| Hypertension      | 460           | 2.49 (2.16–2.88) | <0.001  | 1.36 (1.14–1.62)    | <0.001  |
| Diabetes mellitus | 360           | 2.59 (2.25–2.99) | <0.001  | 1.55 (1.31–1.84)    | <0.001  |
| Coronary artery disease | 303 | 2.05 (1.78–2.37) | <0.001  | 1.12 (0.95–1.33)    | 0.18    |
| Hyperlipidemia    | 286           | 1.59 (1.37–1.84) | <0.001  | 1.13 (0.96–1.32)    | 0.14    |
| Liver cirrhosis   | 180           | 2.02 (1.71–2.39) | <0.001  | 1.54 (1.29–1.83)    | <0.001  |
| Heart failure     | 65            | 2.84 (2.2–3.66)  | <0.001  | 1.61 (1.23–2.11)    | <0.001  |
| Osteoporosis      | 147           | 1.74 (1.45–2.08) | <0.001  | 0.99 (0.82–1.21)    | 0.96    |
| Arrhythmia        | 112           | 1.57 (1.29–1.92) | <0.001  | 0.97 (0.78–1.2)     | 0.78    |
| PVD               | 23            | 1.49 (0.98–2.26) | 0.06    | 0.96 (0.63–1.46)    | 0.85    |
| Medication        |               |                 |         |                     |         |
| HBV drug          | 22            | 0.68 (0.45–1.04) | 0.08    | 0.73 (0.47–1.12)    | 0.15    |
| HCV drug          | 29            | 0.44 (0.3–0.63)  | <0.001  | 0.45 (0.31–0.65)    | <0.001  |
| CKD drug          | 557           | 1.86 (1.58–2.17) | <0.001  | 0.78 (0.65–0.95)    | 0.01    |
| DM drug           | 253           | 2.24 (1.93–2.6)  | <0.001  | 1.41 (1.18–1.68)    | <0.001  |
| Statin            | 112           | 1.09 (0.89–1.33) | 0.4     | 0.7 (0.56–0.86)     | <0.001  |

CHM, Chinese herbal medicine; SD, standard deviation; PVD, peripheral vascular disease; HBV, hepatitis B virus; hepatitis C virus; CKD, chronic kidney disease; DM, diabetes mellitus; HR, hazard ratio; CI, confidence interval. §Cox model adjusted with gender, age, urbanization, comorbidity and medication.

Figure 2: Cumulative incidence of CKD of both CHM and non-CHM cohorts in patients with hepatitis, by Kaplan–Meier analysis.
Cryoglobulinemia-dependent MPGN in CHC patients is approximately 30% [22] and is considered the most common cause of nephritic or nephrotic syndrome [23]. In a large-scale cohort study (n = 56,448), CHC patients demonstrated an approximately 2-fold and 17-fold risk of developing MPGN and cryoglobulinemia, respectively [24]. Antiviral therapy may be a superior option to protect kidneys by preventing viral proliferation and synthesis of immune-complexes, decreasing immune-complex and cryoglobulin formations, as well as preventing inflammation and vasculitis.

The present study explores the risk factors associated with CKD development in patients with hepatitis, such as male gender, age over 60, hypertension, DM, liver cirrhosis, and heart failure. Moreover, while HCV, CKD, and statin medications can decrease the risk of developing CKD, and DM medications, by contrast, can increase the risk. As previously reported, male gender and age are the primary risk factors associated with the development of MN, while the average onset of MN was in patients’ 50s and 60s of age, compatible with the findings of this study [18]. Meanwhile, hypertension exerts negative effects on the kidneys as it leads

**Table 3: The CHM effect on CKD in subgroups.**

| Subgroup                  | Non-CHM users | CHM users | Crude HR (95%) | Adjusted HR (95%) |
|---------------------------|---------------|-----------|----------------|-------------------|
|                           | Event no. | PY | IR | Event no. | PY | IR |                      |                   |
| HBV                       | 111       | 4216 | 2.63 | 134       | 5562 | 2.41 | 0.89 (0.69–1.15) | 0.81 (0.62–1.05) |
| HCV                       | 153       | 3384 | 4.52 | 281       | 8637 | 3.25 | 0.72 (0.59–0.88)** | 0.65 (0.53–0.8)** |
| HBV and HCV               | 54        | 1469 | 3.68 | 37        | 1334 | 2.77 | 0.75 (0.49–1.14) | 0.6 (0.39–0.92)** |

HBV, hepatitis B virus; hepatitis C virus; PY, person year; IR, incidence rate/100 person-years; HR, hazard ratio; CI, confidence interval. *p < 0.05; **p < 0.01; ***p < 0.001.

**Table 4: Cox proportional hazard regression analysis for the risk of CKD for HBV and HCV medication.**

| Variable | Number | CKD event | Person years | IR | Crude HR (95% CI) | Adjusted HR (95% CI) |
|----------|--------|-----------|--------------|----|------------------|----------------------|
| HBV patients |        |           |              |    |                   |                      |
| CHM | HBV drug |                |              |    |                   |                      |
| No | No | 1169 | 107 | 4054 | 2.64 | Ref. | Ref. |
| No | Yes | 1080 | 134 | 5431 | 2.47 | 0.91 (0.71–1.18) | 0.84 (0.65–1.10) |
| Yes | No | 36 | 4 | 163 | 2.45 | 0.92 (0.34–2.50) | 0.98 (0.36–2.67) |
| Yes | Yes | 23 | 0 | 132 | 0.00 | — | — |
| HCV patients |        |           |              |    |                   |                      |
| CHM | HCV drug |                |              |    |                   |                      |
| No | No | 966 | 148 | 3100 | 4.77 | Ref. | Ref. |
| No | Yes | 1172 | 271 | 8060 | 3.36 | 0.70 (0.57–0.86)** | 0.66 (0.53–0.81)** |
| Yes | No | 58 | 5 | 284 | 1.76 | 0.37 (0.15–0.89)* | 0.52 (0.21–1.28) |
| Yes | Yes | 78 | 10 | 577 | 1.73 | 0.36 (0.19–0.68)** | 0.40 (0.21–0.76)** |
| HCV and HBV patients |        |           |              |    |                   |                      |
| CHM | Both |                |              |    |                   |                      |
| No | No | 420 | 48 | 1258 | 3.82 | Ref. | Ref. |
| No | Yes | 325 | 35 | 1204 | 2.91 | 0.76 (0.49–1.18) | 0.69 (0.44–1.09) |
| Yes | No | 48 | 4 | 154 | 2.59 | 0.68 (0.25–1.89) | 0.69 (0.24–1.97) |
| Yes | Yes | 20 | 2 | 82 | 2.43 | 0.63 (0.15–2.57) | 0.81 (0.19–3.39) |

IR, incidence rates; HR, hazard ratio; CI, confidence interval. Adjusted HR: adjusted for sex, age, and all comorbidities in Cox proportional hazards regression. *p < 0.05; **p < 0.01; ***p < 0.001.

**Table 5: Hazard Ratios and 95% confidence intervals of CKD risk associated with cumulative use day of TCM among hepatitis patients.**

| Event no. | Person year | IR | Hazard ratio (95%) |
|-----------|-------------|----|-------------------|
| Non-TCM users | (n = 770) |     |                    |
| Chinese herb users |       |    |                   |
| 30–60 days | 318 | 9069 | 3.51 | 1.00 (ref.) | 1.00 (ref.) |
| 60–90 days | 144 | 4045 | 3.56 | 0.99 (0.81–1.20) | 0.88 (0.72–1.07) |
| >90 days | 74 | 2253 | 3.28 | 0.91 (0.71–1.17) | 0.82 (0.64–1.06) |
| p for trend | 234 | 9236 | 2.53 | 0.70 (0.58–0.83)** | 0.58 (0.49–0.69)** |

Crude HR* represented relative hazard ratio; adjusted HR† represented adjusted hazard ratio: mutually adjusted with gender, age, urbanization, comorbidity, and medication in Cox proportional hazard regression. *p < 0.05; **p < 0.01; ***p < 0.001.
to increased intraglomerular capillary pressure, podocyte dysfunction, abnormal permeability, and eventual proteinuria. This mechanism can be prevented via angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) [25].

The development of MN or MPGN caused by hepatitis viral infection will lead to nephrotic syndrome, associated with proteinuria. The protein loss results in a decrease of oncotic pressure, and hypoproteinemia will be compensated for by liver genesis lipoprotein; consequently, excess

### Table 6: The top ten single herbs and formulas.

| Single herb                    | Frequency | Total prescription days | Total prescription dose | Average dose | Average days |
|-------------------------------|-----------|-------------------------|-------------------------|--------------|--------------|
| Salviae Miltiorrhizae         | 18286     | 167551                  | 421569.9                | 2.5          | 9.2          |
| Corydalis Rhizoma             | 15145     | 107063                  | 291003.8                | 2.7          | 7.1          |
| Rhei Radix et Rhizoma         | 11676     | 91721                   | 132202.1                | 1.4          | 7.9          |
| Scutellariae Radix            | 11294     | 88082                   | 233831.4                | 2.7          | 7.8          |
| Astragali Radix               | 9310      | 82461                   | 193854.9                | 2.4          | 8.9          |
| Fritillariae Thunbergii Bulbus| 11204     | 81940                   | 216510.7                | 2.6          | 7.3          |
| Platycodonis Radix            | 11343     | 76509                   | 156414.6                | 2            | 6.7          |
| Puerariae Lobatae Radix       | 10186     | 73121                   | 166887.3                | 2.3          | 7.7          |
| Polygoni Multiflori Thumb     | 8094      | 69468                   | 208078.5                | 3            | 8.6          |
| Ziziphi Spinosae Semen        | 8013      | 69061                   | 312031.1                | 4.5          | 8.6          |

### Table 7: Hazard ratios and 95% confidence intervals of mortality risk associated with herbal formulas among hepatitis patients.

| TCM prescription                     | CKD Hazard ratio (95% CI) | Non-TCM user | Single herb | Crude* | Crude† | Adjusted* |
|--------------------------------------|---------------------------|--------------|-------------|--------|--------|-----------|
| Non-TCM user                         |                           | No. of events| Crude*      | Ref.   | Ref.   |           |
| Salviae Miltiorrhizae                |                           | 201          | 0.92 (0.77–1.11) | 0.73 (0.61–0.89)** |        |           |
| Corydalis Rhizoma                    |                           | 194          | 0.87 (0.72–1.05) | 0.74 (0.61–0.89)** |        |           |
| Rhei Radix et Rhizoma                |                           | 108          | 0.95 (0.76–1.18) | 0.75 (0.60–0.95)*  |        |           |
| Scutellariae Radix                   |                           | 145          | 0.76 (0.62–0.94)** | 0.72 (0.58–0.89)** |        |           |
| Astragali Radix                      |                           | 127          | 1.00 (0.81–1.24) | 0.83 (0.67–1.03)   |        |           |
| Fritillariae Thunbergii Bulbus       |                           | 152          | 0.84 (0.69–1.03) | 0.74 (0.60–0.91)** |        |           |
| Platycodonis Radix                   |                           | 153          | 0.95 (0.78–1.15) | 0.81 (0.66–0.99)*  |        |           |
| Puerariae Lobatae Radix              |                           | 143          | 0.82 (0.67–1.00) | 0.71 (0.58–0.88)** |        |           |
| Polygoni Multiflori Thumb            |                           | 93           | 0.80 (0.63–1.01) | 0.69 (0.54–0.88)   |        |           |
| Ziziphi Spinosae Semen               |                           | 96           | 0.86 (0.68–1.08) | 0.76 (0.59–0.96)*  |        |           |

Formula

| Formula                             | TCM prescription | CKD Hazard ratio (95% CI) | Non-TCM user | Single herb | Crude* | Crude† | Adjusted* |
|-------------------------------------|------------------|---------------------------|--------------|-------------|--------|--------|-----------|
| Jia-Wei-Xiao-Yao-San                |                  |                           | 210          | 0.92 (0.77–1.11) | 0.73 (0.61–0.89)** |        |           |
| Xiao-Chai-Hu Tang                   |                  |                           | 11782        | 0.87 (0.72–1.05) | 0.74 (0.61–0.89)** |        |           |
| Shu-jing-huo-xue-tang               |                  |                           | 12959        | 0.95 (0.76–1.18) | 0.75 (0.60–0.95)*  |        |           |
| Ban-Xia-Xie-Xin-Tang                |                  |                           | 11630        | 0.76 (0.62–0.94)** | 0.72 (0.58–0.89)** |        |           |
| Shao-Yao-Gan-Cao-Tang               |                  |                           | 10471        | 1.00 (0.81–1.24) | 0.83 (0.67–1.03)   |        |           |
| Long-Dan-Xie-Gan-Tang               |                  |                           | 8580         | 0.84 (0.69–1.03) | 0.74 (0.60–0.91)** |        |           |
| Suan-Zao-Ren-Tang                   |                  |                           | 9241         | 0.95 (0.78–1.15) | 0.81 (0.66–0.99)*  |        |           |
| Xue-Fu-Zhu-Yu-Tang                  |                  |                           | 8577         | 0.82 (0.67–1.00) | 0.71 (0.58–0.88)** |        |           |
| Xiang-Sha-Liu-Jun-Zi-Tang           |                  |                           | 8040         | 0.80 (0.63–1.01) | 0.69 (0.54–0.88)   |        |           |
| Ping-Wei-San                        |                  |                           | 8777         | 0.86 (0.68–1.08) | 0.76 (0.59–0.96)*  |        |           |

Crude HR* represented relative hazard ratio; adjusted HR† represented adjusted hazard ratio: mutually adjusted for age group, gender, urbanization level, and cci score in Cox proportional hazard regression. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \).
production of low density lipoprotein causes hypercholesteremia. However, hypocholesteremia has been observed in HCV patients due to upregulated lipid biosynthesis and impaired lipid degradation, which leads to intracellular lipid accumulation and facilitates the formation of steatosis and fibrosis [26]. This phenomenon will induce hypoproteinemia and affect the cardiovascular system as a result of hypertension and/or congestive heart failure, becoming risk factors of CKD development in patients with hepatitis. Statin has been reported to control hyperlipidemia, exert powerful anti-HCV effects, and thus reduce the risk of cirrhosis in hepatitis patients [27].

Additionally, DM is a common extrahepatic manifestation associated with HCV infection [22]. The HCV core protein decreases the expression of insulin receptor substrate proteins (IRS) 1 and 2 and causes abnormal insulin sensitivity and beta-cell dysfunction. As such, it activates insulin resistance and hyperinsulinemia, consequently inducing HCV-related diabetic nephropathy [20]. Many DM drug metabolites are eliminated via the kidneys, such as biguanide, sulphonylureas, dipeptidylpeptidase-4 inhibitors, and SGLT-2 inhibitors, possibly burdening renal function [28].

Based on the top 10 most frequently prescribed formulas and single herbs, CHM may prevent CKD incidence among hepatitis patients via directly inhibiting viral expression, preventing liver and kidney damage, treating the comorbidities, and alleviating the side effects induced by interferon. HBV and/or HCV infection will activate the inflammatory process, leading to fibrosis and cirrhosis. According to TCM theory, these phenomena are primarily patterned as hepatobiliary damp-heat. Among the top ten herbs and formulas, XCHT has exhibited anti-HCV activity in a phase II clinical trial [29].

The effects of cryoglobulinemia and immune-complexes cause renal function decline. These, according to TCM theory, can be considered consistent with Qi stagnation and blood stasis. Several CHM herbs and formulas may offer protective effects against both liver and renal function decline. In particular, TCM theory suggests that JWXYS and Xue-Fu-Zhu-Yu-Tang may serve to soothe the liver Qi and relieve blood stasis. Studies have reported that JWXYS may improve the survival rate in HBV patients when combined with lamivudine treatment [30] and decrease the mortality rate and risk of liver cirrhosis in HCV patients [31]. Furthermore, JWXYS has been shown to elevate serum albumin levels and prevent liver fibrosis [32]. Meanwhile, TCM theory suggests that SM, the most commonly prescribed herb identified in this study, can invigorate blood, dispel blood stasis, and cool blood heat. Furthermore, it has been reported that SM prevents immune-mediated liver injury and liver fibrosis through modulating the NF-κB and IFN-γ/STAT1 signaling pathways as well as enhancing NK cell activity [33]. Of note, a recent study revealed renal fibrosis resulting from MN and diabetic nephropathy via the dysregulation of the TGF-β/Smad pathway [34]. This pathway can be regulated by SM and Scutellaria radix to protect renal function from deterioration [35].

On the aspect of treating the comorbidities, XFZYT has not only antiangiogenesis effect that can prevent liver fibrosis [36] but also lowers the blood pressure [37]. Pueraria lobata exerts anti-inflammation effects through regulating the IKKb/IRS-1 pathway and improving endothelial insulin resistance. When combined with SM, the synergistic effects of antihypertension and antiatherosclerosis may effectively reduce the risk of CKD [38, 39]. This correlation was further
observed in the network analysis herein. SM alone can also prevent the development of DM nephropathy via suppressing TGF-β1 and improving renal microcirculation [40]. Other herbal formulas without direct hepatic and renal protective activities may help deal with the interferon side effects. Some HCV patients undergoing pegylated interferon/ribavirin therapy will seek CHM to alleviate side effects and improve quality of life [41]. The common side effects of PEG-IFN include flu-like symptoms (headache, myalgia, and fatigue); digestive discomforts (nausea, loss of appetite, and diarrhea); and neuropsychiatric disorders (insomnia and depression) [42]. Shu-Jing-Huo-Xue-Tang and Shao-Yao-Gan-Cao-Tang have been reported to increase blood circulation and decrease muscle cramps to relieve myalgia [43, 44]. Ban-Xia-Xie-Xin-Tang possesses prokinetic activity and motility regulation to alleviate anorexia and diarrhea [45]. JWXYS and Suan-Zao-Ren-Tang improve insomnia and depression [46]. The other known pharmacological mechanisms of the top ten single herbs and formulas are illustrated in Supplementary Tables 2 and 3.

Although the new generation of NAs and DAAs provides hepatitis patients with effective treatment options, high costs may restrict their popularity and availability, particularly in developing countries. By contrast, CHM treatments offer more cost-effective management strategies. This study demonstrates that CHM provided protective effects against development of CKD for HCV patients. Therefore, the use of CHM as an adjuvant therapy strategy warrants consideration by medical practitioners.

Inevitably, the analysis of data extracted from the NHIRD has limitations. First, laboratory data, images, pathology reports, and patient lifestyle details are not recorded in the database. Second, the diagnostic records were based on ICD-9, which lacks data regarding CKD severity; ICD-10 provides more information (ICD-10 code: N181–N189) regarding the severity of CKD. Third, some CKD risk factors, such as proteinuria, smoking, herbal supplement therapy, intravenous drug use, and human immunodeficiency virus infection were not included in this study. Fourth, we did not exclude the influence from hepatitis D virus infection among CHB groups. Furthermore, patients’ CHM compliance cannot be shown by NHIRD.

5. Conclusions

The database analysis of this study reveals that CHM as an adjunctive therapy decreased incidence of CKD in Taiwanese patients with hepatitis C. These findings suggest that future research into complementary and alternative medicine treatments for patients with hepatitis C is warranted. However, future prospective cohort research is recommended to ascertain and elucidate the specific CHM mechanisms associated with CKD prevention in hepatitis patients.

Abbreviations

| Abbreviation | Definition                        |
|--------------|----------------------------------|
| CHC          | Chronic hepatitis C              |
| CHM          | Chinese herbal medicine          |
| CI           | Confidence interval              |
| CKD          | Chronic kidney disease           |
| DAAs         | Direct-acting antivirals          |
| DM           | Diabetes mellitus                |
| ESRD         | End-stage renal disease           |
| ESRF         | End-stage renal failure           |
| HBV          | Hepatitis B virus                |
| HCV          | Hepatitis C virus                |
| ICD-9-       | International Classification of Disease, Ninth |
| CM           | Revision, Clinical Modification   |
| IFN          | Interferon                       |
| JWXYS        | Jia-Wei-Xiao-Yao-San             |
| MN           | Membranous nephropathy           |
| MPGN         | Membranoproliferative glomerulonephritis |
| NAs          | Nucleoside analogs               |
| NHI          | National Health Insurance        |
| SM           | Salvia Miltiorrhiza              |
| TCM          | Traditional chinese medicine      |
| XCHT         | Xiao-Chai-Hu Tang                |
| XFZYT        | Xue-Fu-Zhu-Yu-Tang               |

Data Availability

The dataset is provided from Taiwan’s National Health Research Institutes (http://nhird.nhri.org.tw).

Ethical Approval

The Research Ethics Committee of China Medical University and Hospital in Taiwan approved this study (CMUH-104-REC2-115-R3). As all of the datasets were deidentified from LHID 2000, the review board waived the requirement for obtaining informed consent from patients.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

CPC wrote the manuscript and interpreted the data. YCS and MCL collected, assembled, and analyzed the data. STH designed, conceived the study, and amended the manuscript. All of the authors approved the final manuscript.

Acknowledgments

This work was supported and funded by Health and Welfare Surcharge of Tobacco Products, China Medical University Hospital Cancer Research Center of Excellence (MOHW108-TDU-B-212-124024), China Medical University Hospital (DMR-108-007, DMR-108-009, DMR-108-044, DMR-107-164, and CRS-106-001), and Chinese Medicine Research Center, China Medical University under the Higher Education Sprout Project, Ministry of Education (CMRC-CHM-1) in Taiwan. This work was also supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University
Hospital, Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 107-2321-B-039 -004-), Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The authors would like to thank James Waddell of Concise Language Services for the critical reading and revision of our manuscript.

**Supplementary Materials**

Supplementary Table 1: incidence rates, hazard ratio, and confidence intervals of CKD in different stratifications correlated with comorbidities. Multivariable stratified analyses were applied to verify the association of hepatitis patients with CHM treatment to reduce CKD risk for those comorbidities. Supplementary Table 2: the hepatic and renal protective activities associated with experimental models of extracted ingredients of single herbs. The known pharmacological mechanisms of the top ten single herbs were associated with liver and renal protection by cell and/or animal experimental studies. Supplementary Table 3: the compositions as well as hepatic and renal protective activities associated with experimental models of top ten formulas. The compositions and hepatic protection of the top ten formulas were illustrated. (Supplementary Materials)

**References**

[1] W. H. Organization, *Global Hepatitis Report 2017*, World Health Organization, Geneva, Switzerland, 2017.

[2] Y. C. Chen, Y. C. Su, C. Y. Li, and S. K. Hung, "13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan," *BM J Nephrology*, vol. 16, p. 110, 2015.

[3] Y.-C. Chen, H.-Y. Lin, C.-Y. Li, M.-S. Lee, and Y.-C. Su, "A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease," *Kidney International*, vol. 85, no. 5, pp. 1200–1207, 2014.

[4] R. Bhimma and H. M. Coovadia, "Hepatitis B virus-associated nephropathy," *American Journal of Nephrology*, vol. 24, no. 2, pp. 198–211, 2004.

[5] C. A. Solid, S. A. Peter, T. Natwick, H. Guo, A. J. Collins, and J. M. Arduinary, "Impact of renal disease on patients with hepatitis C: a retrospective analysis of disease burden, clinical outcomes, and health care utilization and cost," *Nephron*, vol. 136, no. 2, pp. 54–61, 2017.

[6] S. Marinaki, J. N. Boletis, S. Sakellariou, and I. K. Delladetsima, "Hepatitis C in hemodialysis patients," *World Journal of Nephrology*, vol. 7, no. 3, pp. 548–558, 2015.

[7] A. E. Mikolajczyk and A. I. Aronsohn, "Current management of chronic hepatitis B and C in chronic kidney disease," *Advances in Chronic Kidney Disease*, vol. 22, no. 5, pp. 352–360, 2015.

[8] C. Pipili, E. Cholongitas, and G. Papatheodoridis, "Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease," *Antimicrobial Pharmacology & Therapeutics*, vol. 39, no. 1, pp. 35–46, 2014.

[9] C. L. Pipili, G. V. Papatheodoridis, and E. C. Cholongitas, "Treatment of hepatitis B in patients with chronic kidney disease," *Kidney International*, vol. 84, no. 5, pp. 880–885, 2013.

[10] S. Pol, L. Parlati, and M. Jadoul, "Hepatitis C virus and the kidney," *Nature Reviews Nephrology*, vol. 15, no. 2, pp. 73–86, 2018.

[11] P. Carrier, M. Essig, M. Debette-Gratien et al., "Anti-hepatitis C virus drugs and the kidney," *World Journal of Hepatology*, vol. 8, no. 32, pp. 1343–1353, 2016.

[12] M. H. Nguyen, J. K. Lim, A. B. Ozbay et al., "Higher resource utilization and healthcare costs in treated chronic hepatitis B patients with chronic kidney disease," *Gastroenterology*, vol. 152, no. 5, p. S1083, 2017.

[13] A. Puenpatom, M. Hull, J. McPheeters, and K. Schweske, "Disease burden, early discontinuation, and healthcare costs in hepatitis C patients with and without chronic kidney disease treated with interferon-free direct-acting antiviral regimens," *Clinical Drug Investigation*, vol. 37, no. 7, pp. 687–697, 2017.

[14] T. Y. Tsai, H. Livneh, T. H. Hung, I. H. Lin, M. C. Lu, and C. C. Yeh, "Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study," *BMJ Open*, vol. 7, no. 1, Article ID e014571, 2017.

[15] C. Y. Liu, J. Y. Chu, H. R. Yen, and C. H. Hsu, "Utilization and prescription patterns of traditional Chinese medicine for patients with hepatitis C in Taiwan: a population-based study," *BMJ Complementary and Alternative Medicine*, vol. 16, no. 1, p. 397, 2016.

[16] K.-C. Huang, Y.-C. Su, M.-F. Sun, and S.-T. Huang, "Chinese herbal medicine improves the long-term survival rate of patients with chronic kidney disease in Taiwan: a nationwide retrospective population-based cohort study," *Frontiers in Pharmacology*, vol. 9, no. 1117, 2018.

[17] K. N. Lai, P. K. T. Li, S. F. Lui et al., "Membranous nephropathy related to hepatitis B virus in adults," *New England Journal of Medicine*, vol. 324, no. 21, pp. 1457–1463, 1991.

[18] R. Glassock, "Diagnosis and natural course of membranous nephropathy," *Seminars in Nephrology*, vol. 23, no. 4, pp. 324–332, 2003.

[19] Y.-C. Chen, Y.-Y. Li, C.-P. Wu, and M.-S. Lee, "A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan," *Kidney International*, vol. 87, no. 5, pp. 1030–1038, 2015.

[20] A. Ozkok and A. Yikiz, "Hepatitis C virus associated glomerulopathies," *World Journal of Gastroenterology*, vol. 20, no. 24, pp. 7544–7554, 2014.

[21] F. Fabrizi, E. Plaisier, D. Saadoun, P. Martin, P. Messa, and P. Cacoub, "Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease," *American Journal of Kidney Diseases*, vol. 61, no. 4, pp. 623–637, 2013.

[22] V. Agnello and F. G. De Rosa, "Extrahepatic disease manifestations of HCV infection: some current issues," *Journal of Hepatology*, vol. 40, no. 2, pp. 341–352, 2004.

[23] L. Spatola, E. Generali, C. Angelini, S. Badalamenti, and C. Selmi, "HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases," *Clinical and Experimental Medicine*, vol. 18, no. 4, pp. 465–471, 2018.

[24] P. Pontisso, M. G. Ruvoletto, G. Fattovich et al., "Clinical and virological profiles in patients with multiple hepatitis virus infections," *Gastroenterology*, vol. 105, no. 5, pp. 1529–1533, 1993.
Evidence-Based Complementary and Alternative Medicine

[25] P. Ruggenenti, P. Cravedi, and G. Remuzzi, “Mechanisms and treatment of CKD,” *Journal of the American Society of Nephrology*, vol. 23, no. 12, pp. 1917–1928, 2012.

[26] T. G. Simon and A. A. Butt, “Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes,” *World Journal of Gastroenterology*, vol. 21, no. 27, pp. 8293–8303, 2015.

[27] Y.-W. Huang, C.-L. Lee, S.-S. Yang et al., “Statins reduce the risk of cirrhosis and its decapsulation in chronic hepatitis B patients: a nationwide cohort study,” *American Journal of Gastroenterology*, vol. 111, no. 7, pp. 976–985, 2016.

[28] M. Abe, K. Okada, and M. Soma, “Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice,” *Current Drug Metabolism*, vol. 12, no. 1, pp. 57–69, 2011.

[29] J. Xia, Y. Inagaki, P. Song et al., “Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus,” *Bioscience Trends*, vol. 10, no. 5, pp. 327–336, 2016.

[30] D.-S. Tsai, M.-H. Huang, Y.-S. Chang, T.-C. Li, and W.-H. Peng, “The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment,” *Journal of Ethnopharmacology*, vol. 174, pp. 161–167, 2015.

[31] F.-J. Tsai, C.-F. Cheng, C.-J. Chen et al., “Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan,” *Phytotherapy Research*, vol. 57, pp. 30–38, 2019.

[32] S.-C. Chien, W.-C. Chang, P.-H. Lin et al., “A Chinese herbal medicine, Jia-Wei-Xiao-Yao-San, prevents dimethylnitrosamine-induced hepatic fibrosis in rats,” *TheScientificWorldJournal*, vol. 2014, Article ID 217525, 7 pages, 2014.

[33] Y. Peng, T. Yang, K. Huang, L. Shen, Y. Tao, and C. Liu, “Salvia miltiorrhiza ameliorates liver fibrosis by activating hepatic natural killer cells in vivo and in vitro,” *Frontiers in Pharmacology*, vol. 9, p. 762, 2018.

[34] L. Chen, T. Yang, D.-W. Lu et al., “Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment,” *Biomedicine & Pharmacotherapy*, vol. 101, pp. 670–681, 2018.

[35] H.-H. Hu, D.-Q. Chen, Y.-N. Wang et al., “New insights into TGF-β/Smad signaling in tissue fibrosis,” *Chemico-Biological Interactions*, vol. 292, pp. 76–83, 2018.

[36] Y.-N. Zhou, M.-Y. Sun, Y.-P. Mu et al., “Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl₄ in mice,” *Journal of Ethnopharmacology*, vol. 153, no. 3, pp. 659–666, 2014.

[37] P. Wang, X. Xiong, and S. Li, “Efficacy and safety of a traditional Chinese herbal formula xuefuzhuyu decoction for hypertension: a systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 94, no. 42, Article ID e1850, 2015.

[38] C. M. Koon, K. S. Woo, P. C. Leung, and K. P. Fung, “Salviae Miltiorrhizae Radix and Puerariae Lobatae Radix herbal formula mediates anti-atherosclerosis by modulating key atherogenic events both in vascular smooth muscle cells and endothelial cells,” *Journal of Ethnopharmacology*, vol. 138, no. 1, pp. 175–183, 2011.

[39] C. F. Ng, C. M. Koon, D. W. S. Cheung et al., “The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation,” *Journal of Ethnopharmacology*, vol. 137, no. 3, pp. 1366–1372, 2011.

[40] L. He, H. Wang, C. Gu, X. He, L. Zhao, and X. Tong, “Administration of traditional Chinese blood circulation activating drugs for microvascular complications in patients with type 2 diabetes mellitus,” *J Diabetes Res*, vol. 2016, Article ID 1081657, 7 pages, 2016.